Bởi Maksym Misichenko · Nasdaq ·
Các tác nhân AI nghĩ gì về tin tức này
Both KMB and CLX face significant execution risks and structural challenges, with high debt levels and retailer concentration. The market may be underpricing these risks.
Rủi ro: High debt levels and potential regulatory hurdles for KMB, and retailer concentration and private-label erosion for CLX.
Cơ hội: None identified.
Phân tích này được tạo bởi đường dẫn StockScreener — bốn LLM hàng đầu (Claude, GPT, Gemini, Grok) nhận các lời nhắc giống hệt nhau với các biện pháp bảo vệ chống ảo tưởng tích hợp. Đọc phương pháp →
Kimberly-Clark maintains a dominant global presence with essential personal care brands like Huggies and Kleenex.
The Clorox Company holds a strong market share in the household cleaning and bleach categories with brands like Pine-Sol and Brita.
Which of these household staples is the better addition to your portfolio for 2026?
Choosing between stable dividends and market-leading brands often leads investors to Kimberly-Clark (NASDAQ:KMB) and The Clorox Company (NYSE:CLX), but which of these household giants offers better value for the year ahead?
Kimberly-Clark focuses on paper-based personal care essentials like diapers and tissues, while Clorox dominates the cleaning and bleach categories. Both companies navigate high commodity costs and intense competition. Investors often compare them because they provide consistent products that consumers buy regardless of the economic climate.
Kimberly-Clark produces essential personal care and family care products under recognizable brands including Huggies, Kleenex, Poise, and Cottonelle. Its primary customers include large retailers that are considered leading consumer staples stocks in their own right. Walmart accounts for approximately 16% of net sales from continuing operations, and such customer concentration adds a layer of risk to the business.
In FY 2025, revenue reached nearly $16.4 billion, down from $16.8 billion in the prior year as the company navigated shifting consumer demand. Net income for the fiscal year was approximately $2.0 billion, a decline compared to the $2.5 billion reported during the 2024 fiscal period. This resulted in a net margin of approximately 12.2%, which represents the percentage of each dollar of sales that becomes profit after all expenses.
The company reported a debt-to-equity ratio of nearly 4.8x as of its December 2025 balance sheet, a metric that measures total debt relative to shareholders' equity. Its current ratio is roughly 0.7x, which compares short-term assets to short-term liabilities to help investors assess immediate liquidity. Free cash flow for the period totaled nearly $1.6 billion, reflecting cash from operations minus capital expenditures, providing the business with capital for dividends or reinvestment.
The Clorox Company manufactures a diverse range of products, including cleaning supplies, food storage, and water filtration, under brands such as Brita, Pine-Sol, and Clorox. It maintains a strong presence in the market for everyday cleaning and bleach products, regardless of the economy. Walmart and its affiliates accounted for nearly 27% of net sales in FY 2025, and such customer concentration adds a layer of risk to the business.
For the fiscal year ending in 2025, the company generated nearly $7.1 billion in revenue, essentially flat compared to the previous year. Net income rose significantly to approximately $810.0 million, up from $280.0 million in the 2024 fiscal period as profitability recovered. This improvement led to a net margin of roughly 11.4%, which is the amount of profit the company retains from its total sales after all costs.
Clorox reported a debt-to-equity ratio of approximately 9.0x as of June 2025, indicating that its total debt is quite high relative to its shareholders’ equity. The current ratio is roughly 0.8x, which measures the ability to cover short-term obligations with short-term assets such as cash and inventory. Free cash flow for the fiscal year totaled nearly $761.0 million, the cash remaining after paying for operations and capital expenditures to support growth.
Kimberly-Clark faces intense competition from Procter & Gamble and generic store brands, which requires significant spending on advertising and innovation to maintain market share. Geopolitical instability and currency fluctuations affect half of its sales that occur outside the United States, further complicating its operational risks.
Clorox faces significant customer concentration risk, as Walmart and its affiliates accounted for nearly 27% of net sales in FY 2025. This gives large retailers the power to demand lower pricing or prioritize their own private-label products. Cybersecurity also remains a concern following a major 2023 incident, alongside the execution risks and potential business disruptions associated with a large-scale software upgrade.
Kimberly-Clark currently appears to be the more affordable option based on its Forward P/E relative to future earnings estimates, though both companies trade at lower multiples than the broader sector average.
| Metric | Kimberly-Clark | The Clorox | Sector Benchmark | |---|---|---|---| | Forward P/E | 13.2x | 17.4x | 25.5x | | P/S ratio | 1.9x | 1.6x |
Sector benchmark uses the SPDR XLP sector ETF.Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.
While both of these stocks are interesting in their own ways, investors must realize that they each are in full-blown turnaround mode. First, Kimberly-Clark is selling 51% of its international tissue business to Suzano to streamline its operations. Rather than managing 22 factories with operations in over 70 countries, KMB will let the Brazilian-based pulp manufacturer handle its global operations, while licensing its brands to the company. Meanwhile, Kimberly-Clark also announced a massive $48 billion potential merger with consumer goods behemoth (and recent Johnson & Johnson spinoff) Kenvue.
The idea of this merger makes a lot of sense to me, as the combined company would create a personal care juggernaut. However, it certainly ups the ante for current and prospective Kimberly-Clark shareholders, as its debt load would have to soar to complete the deal. Because of these pending deals and the integration risks they entail, I’d prefer to wait a few quarters to let the dust settle and see more financial details.
As for Clorox, the company is in a turnaround of its own, following a growth slowdown after its pandemic-aided boost and a massive 2023 cyberattack that it is still recovering from financially. However, Clorox’s margins are gradually trending back to their pre-cyberattack and pre-pandemic levels, yet its P/S ratio of 1.7 remains near a decade-long low, and well below its 10-year average of 2.9.
If you’re looking to hit a “home run,” so to speak, with these stocks, KMB probably offers more outperformance potential, albeit with higher risk, thanks to all of its moving parts. That said, I would lean toward the slightly safer Clorox (historically speaking, setting aside the cyberattack), which generates 80% of its sales from brands that are No. 1 or No. 2 in their niche.
Before you buy stock in Kimberly-Clark, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Kimberly-Clark wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $471,072! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,303,352!
Now, it’s worth noting Stock Advisor’s total average return is 983% — a market-crushing outperformance compared to 210% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of May 28, 2026. *
Josh Kohn-Lindquist has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Kenvue and Walmart. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Bốn mô hình AI hàng đầu thảo luận bài viết này
"Neither stock offers a margin of safety once the undisclosed merger financing and retailer concentration risks are modeled into 2026 cash flows."
The article correctly flags both names' Walmart concentration and commodity exposure but underplays execution risk on KMB's proposed Kenvue merger and Suzano tissue sale, which could spike leverage well above the already elevated 4.8x D/E. Clorox's 9.0x debt ratio and 27% Walmart exposure create similar fragility, while its post-cyberattack margin recovery remains unproven at scale. Forward multiples of 13.2x and 17.4x look cheap only if volume stabilizes; any retailer pushback on pricing would compress FCF faster than the sector benchmark implies.
The Kenvue deal could close cleanly and deliver immediate cost synergies that offset KMB's debt spike, while Clorox's #1/#2 brand positions allow faster pricing power than the article's risk section admits.
"Both stocks are cheap because they're executing high-risk restructurings simultaneously, not because they're undervalued relative to risk."
The article frames this as a 'which is better' choice, but both companies are structurally compromised right now. KMB's 4.8x debt-to-equity balloons to unknowable levels post-Kenvue merger ($48B deal), and the Suzano tissue sale strips 51% of international ops—integration risk is massive. CLX's 9.0x leverage is already alarming; the 2023 cyberattack recovery narrative masks that Walmart represents 27% of sales (vs. KMB's 16%), giving CLX less pricing power. Both trade below sector multiples, but that's not a bargain—it's the market pricing in execution risk. The article's conclusion to 'wait on KMB, buy CLX' ignores that CLX's margin recovery is fragile and dependent on Walmart not squeezing harder.
If the Kenvue merger closes cleanly and KMB successfully licenses brands to Suzano while shedding capital-intensive tissue ops, the combined entity could command premium multiples on higher margins—the 'home run' case isn't fiction, just binary.
"Both KMB and CLX are facing existential balance sheet risks that make their dividend profiles unsustainable in the face of aggressive private-label competition."
The article's discussion of a potential $48 billion KMB-Kenvue merger is a massive red flag. If Kimberly-Clark attempts such a transformative acquisition while already carrying a 4.8x debt-to-equity ratio, the balance sheet strain could force a dividend cut—the primary reason investors hold these staples. Clorox, meanwhile, is priced for a recovery that may be slower than expected; a 9.0x debt-to-equity ratio in a high-interest-rate environment effectively caps their ability to reinvest in R&D or defend against private-label encroachment. Both companies are essentially 'value traps' masquerading as safe havens. The market is ignoring the structural decline in pricing power these legacy brands face against retail giants like Walmart.
If KMB successfully offloads its low-margin international tissue business to Suzano, the resulting margin expansion could justify the debt load, turning the company into a leaner, higher-ROIC machine.
"Turnaround upside hinges on uncertain mega-deals and margin recovery, while leverage and retailer concentration risk could cap any upside."
Despite the headline appeal of 'household staples' turnarounds, the article skews toward upside without fully sizing the risks. KMB trades at a cheaper forward multiple (13.2x) than CLX (17.4x), but its debt-to-equity around 4.8x and a 0.7x current ratio highlight funding and liquidity risks if a renewal cycle stalls. The Suzano tissue spin-off and a potential $48 billion Kenvue merger are meaningful but uncertain bets that could saddle equity with leverage rather than durable earnings growth. CLX carries heavier retailer concentration (about 27% of sales with Walmart) and residual cybersecurity risk, while margins remain sensitive to input costs. Both remain turnaround stories; I’d stay neutral.
The strongest countercase is that the execution of the Suzano spin-off and the Kenvue deal could unlock real value and margin expansion, while CLX’s retailer exposure may prove manageable with pricing power; both could surprise on the upside if macro conditions stabilize and cost pressures ease.
"FTC blocks and private-label volume losses create unpriced downside beyond the debt concerns already raised."
Gemini flags dividend risk from the Kenvue deal but misses FTC regulatory blocks that could strand KMB with debt and no synergies after the Suzano sale. CLX faces unpriced private-label volume erosion from inflation, hitting its 27% Walmart exposure harder than leverage metrics show. The 13.2x and 17.4x multiples already embed these execution binaries without upside optionality.
"Regulatory delay on Kenvue creates a worse scenario than outright rejection: trapped capital and forced deleveraging."
Grok raises FTC blocking risk on Kenvue—legitimate—but the real trap is timing. If the deal stalls mid-2024, KMB sits with Suzano proceeds committed but can't deploy them for deleveraging without admitting the merger failed. That's a liquidity cliff nobody's priced. CLX's private-label erosion at Walmart is real, but 27% concentration also means CLX has negotiating leverage Walmart can't ignore; they need Clorox's brand moat more than vice versa.
"Walmart's private-label quality parity has neutralized Clorox's historical pricing leverage, turning their high retailer concentration into a significant structural liability."
Claude, your assertion that Walmart needs Clorox’s brand moat is outdated. Walmart’s 'Great Value' private-label strategy has reached parity in quality for basic cleaning agents, directly eroding Clorox’s pricing power. This isn't just about negotiation; it is about shelf-space utility. If CLX fails to demonstrate clear product superiority, they lose the leverage you assume exists. The 27% concentration is a vulnerability, not a moat, as Walmart can effectively throttle CLX's volume to favor their own margins.
"Walmart's rising private-label push erodes CLX's shelf-space moat, making volume erosion a core risk that could slow margin recovery more than price dynamics alone."
Responding to Gemini: CLX's 27% Walmart exposure isn’t just pricing power risk—it's a structural volume risk. Walmart’s private-label push and promotional tactics threaten CLX’s shelf-space dominance, meaning margin recovery could be undercut even if inflation abates. In other words, the moat may erode with volume, not just price, making CLX's recovery potentially slower and more dependent on Walmart concessions than the article implies today.
Both KMB and CLX face significant execution risks and structural challenges, with high debt levels and retailer concentration. The market may be underpricing these risks.
None identified.
High debt levels and potential regulatory hurdles for KMB, and retailer concentration and private-label erosion for CLX.